Page 143 - Simplicity is Key in CRT

References
1. Bristow MR, et al., Comparison of Medical Therapy P, Defibrillation in Heart Failure I. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350(21):2140-50.
2. Cleland JG, et al., Cardiac Resynchronization-Heart Failure Study I. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352(15):1539-49.
3. McMurray JJ, et al., ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Devel- oped in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14(8):803-69.
4. Ambrosy AP, et al., The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63(12):1123-33.
5. Boriani G, et al. Cost-effectiveness of cardiac resynchronization therapy. Heart 2012;98(24):1828-36.
6. Rohde LE, et al. Cost-effectiveness of heart failure therapies. Nat Rev Cardiol 2013;10(6):338-54.
7. Brignole M, et al., 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac
pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the
European Heart Rhythm Association (EHRA). Eur Heart J 2013;34(29):2281-329.
8. Tracy CM, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm
abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Prac-
tice Guidelines and the Heart Rhythm Society. [corrected]. Circulation 2012;126(14):1784-800.
9. Yancy CW, et al., 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation
2013;128(16):1810-52.
10. Bogale N, et al. The European cardiac resynchronization therapy survey: patient selection and implantation practice vary
according to centre volume. Europace 2011;13(10):1445-53.
11. Marinskis G, et al. Practices of cardiac implantable electronic device follow-up: results of the European Heart Rhythm
Association survey. Europace 2012;14(3):423-5.
12. Curtis AB, et al. Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF. Am Heart J
2009;158(6):956-64.
13. Daubert JC, et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: im-
plant and follow-up recommendations and management. Heart Rhythm 2012;9(9):1524-76.
14. Swedberg K, et al. Successful treatment of heart failure with devices requires collaboration. Eur J Heart Fail
2008;10(12):1229-35.
15. Tang WH, Boehmer J, Gras D. Multispecialty approach: the need for heart failure disease management for refining cardiac
resynchronization therapy. Heart Rhythm 2012;9(8 Suppl):S45-50.
16. Singh JP. Electrical therapy for advanced heart failure: is it time for a multidisciplinary approach or a new subspecialty?
Expert Rev Cardiovasc Ther 2007;5(5):811-5.
17. Fonarow GC, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with
heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure
(OPTIMIZE-HF). Arch Intern Med 2007;167(14):1493-502.
18. Fonarow GC, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of
the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circu-
lation 2010;122(6):585-96.
19. Korantzopoulos P, et al. Anticoagulation and antiplatelet therapy in implantation of electro- physiological devices. Eu-
ropace 2011;13(12):1669-80.
20. Tompkins C, Henrikson CA. Optimal strategies for the management of antiplatelet and anticoagulation medications prior
to cardiac device implantation. Cardiol J 2011;18(1):103-9.
21. Baddour LM, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific
statement from the American Heart Association. Circulation 2010;121(3):458-77.
22. Dyer MT, et al. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes
2010;8:13.
23. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33(5):337-43.
24. Bjelland I, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res
2002;52(2):69-77.
25. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67(6):361-70.
143